Servicenavigation

Project Details

Back

Projekt Print View

EXC 114:  Munich Center for Integrated Protein Science (CIPSM)

Subject Area Basic Research in Biology and Medicine
Term from 2006 to 2019
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 24286268
 
Final Report Year 2019

Final Report Abstract

Proteins are the principal carriers of function in each living cell and of central importance in life. At the beginning of the cluster it became apparent that proteins will be the next generation pharmaceuticals. Indeed today, proteins have revolutionized the way in which we treat cancer. The goal of the excellence cluster CIPSM was to chaperone these new developments. The CIPSM cluster established towards this goal six research areas. In the first research area, protein biophysics, CIPSM studied the stability of proteins and the forces that shape the protein universe. In the second research area CIPSM investigated the principles of proteins folding and misfolding. The third research area was devoted to study the three-dimensional structure of proteins with X-ray crystallography, cryo-electron microscopy and NMR spectroscopy. The fourth research area bundled research in the area of protein nucleic acids interactions, recognizing that proteins are intimately involved in the regulation of transcription. In the fifth research area of CIPSM, new chemical biology and protein engineering tools were developed to manipulate proteins. In research area six, CIPSM investigated proteins involved in diseases with particular emphasis on developing photo-pharmacological approaches, and protein function in systems. Systems biology was newly established in Munich by CIPSM. In all six research areas, CIPSM was able to achieve major scientific breakthroughs as demonstrated by over 2400 publications, among them 25 publications in Nature, 27 publications in Science and 15 publications in Cell. CIPSM also successfully moved scientific results into applications. The elucidation of the silk protein structure and the development of efficient expression systems led not only to high impact publications but allowed the creation of the company AMSilk GmbH. New click chemistry methods were developed to manipulate biomolecules, which delivered not only highly cited publications but led also to the establishment of the company Baseclick GmbH which now provides technologies for next generation sequencing. The CIPSM effort to create highly potent antibodies led to the development of camel-bodies and the spin-outs ChromoTek GmbH and Tubulis GmbH. New ideas to control the cellular half-life time of proteins resulted in the discovery of the Pasylation concept and foundation of the company XL-protein GmbH. The idea to turn fundamental research results into application allowed CIPSM to establish a strategic alliance with Bayer AG. Prof. Plischke, a former board member at Bayer AG and now member of the supervisory board, is teaching courses on innovation management at CIPSM attended by about 100 graduate students from TUM and LMU. CIPSM was able to submit four successful proposals for new research buildings (Bavarian NMR Center, BioSysM, CPA, and ICEM). This expands the laboratory space on the Campus Großhadern-Martinsried and Garching significantly, with an investment that exceeds 160 million Euros.

Link to the final report

https://dx.doi.org/10.2314/GBV:1696292794

Publications

 
 

Additional Information

© 2025 DFG Disclaimer / Copyright / Privacy Policy

Textvergrößerung und Kontrastanpassung